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Abstract
 
Erythrocytes infected with mature forms of 
 
Plasmodium falciparum
 
 do not circulate but are with-
drawn from the peripheral circulation; they are bound to the endothelial lining and to unin-
fected erythrocytes in the microvasculature. Blockage of the blood flow, hampered oxygen de-
 
livery, and severe malaria may follow if binding is excessive. The NH
 
2
 
-terminal head structure
 
(Duffy binding–like domain 1 [DBL1
 
a
 
]–cysteine-rich interdomain region [CIDR1
 
a
 
]) of a sin-
gle species of 
 
P. falciparum
 
 erythrocyte membrane protein 1 (PfEMP1) is here shown to mediate
adherence to multiple host receptors including platelet-endothelial cell adhesion molecule 1
(PECAM-1)/CD31, the blood group A antigen, normal nonimmune immunoglobulin M,
three virulence-associated receptor proteins, a heparan sulfate–like glucosaminoglycan, and
CD36. DBL2
 
d
 
 was found to mediate additional binding to PECAM-1/CD31. The excep-
tional binding activity of the PfEMP1 head structure and its relatively conserved nature argues
that it holds an important role in erythrocyte sequestration and therefore in the virulence of the
malaria parasite.
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Introduction
 
Severe malaria is
 
 
 
brought about at least in part
 
 
 
by the se-
questration of 
 
Plasmodium falciparum
 
–infected erythrocytes
(parasited RBCs [pRBCs]
 
1
 
) in postcapillary venules.
 
 
 
A lo-
cal excessive accumulation of both pRBCs and uninfected
erythrocytes (RBCs) leading to cessation of the local blood
supply is thought to be one explanation for the occurrence
of cerebral and most other forms of severe malaria (1). Par-
asite sequestration is due to the adherence of pRBCs to the
vascular endothelium (cytoadherence) and to erythrocytes
(rosetting) through multiple endothelial and erythrocyte
receptors (2–13).
 
P
 
. 
 
falciparum
 
–infected erythrocytes that both adhere to
the vascular endothelium and form rosettes are more fre-
quently found in individuals with severe than in those with
mild malaria (14–18). It was recently established that pa-
tients with severe malaria carry pRBCs that bind to multi-
ple endothelial and erythrocyte receptors (our unpublished
data). Such parasites were therefore generated in vitro
 
 
 
by
phenotypic selection using micromanipulation of the para-
site FCR3S1 (19). A good example is clone FCR3S1.2,
where the pRBCs not only form rosettes and autoaggluti-
nates but also readily bind to platelet-endothelial cell adhe-
sion molecule 1 (PECAM-1)/CD31, CD36, IgM, the
blood group antigen A, and to a heparan sulfate (HS)-like
glycosaminoglycan (GAG) (7, 11, 12, 19). Stable in vitro–
cloned parasites that so mimic the polyadhesive phenotype
of pRBCs of patients with severe malaria can thus be ex-
plored.
There is compelling evidence that 
 
P. falciparum
 
 erythro-
cyte membrane protein 1 (PfEMP1) is an adhesin (10, 12,
20–24), but whether it is the only adhesin and how it is in-
volved in binding to different receptors remain to be ex-
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Abbreviations used in this paper:
 
 aa, amino acid(s); ALP, alkaline phos-
phatase; CHO, Chinese hamster ovary; CIDR, cysteine-rich interdomain
region; DBL, Duffy binding–like; GAG, glycosaminoglycan; GST, glu-
tathione 
 
S
 
-transferase; HS, heparan sulfate; ICAM-1, intracellular adhe-
sion molecule 1; PECAM-1, platelet-endothelial cell adhesion molecule
1; PfEMP1, 
 
P. falciparum
 
 erythrocyte membrane protein 1; pRBC, para-
sited RBC; RT, reverse transcriptase. 
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plored. Here, we provide evidence that PfEMP1 is a multi-
adhesive parasite ligand and that most of the activity is
localized to the semiconserved head structure composed of
the Duffy binding–like domain 1 (DBL1
 
a
 
) and the cys-
teine-rich interdomain region (CIDR1
 
a
 
) mediating the
binding to several independent host receptors.
 
Materials and Methods
 
The Parasite.
 
FCR3S1.2 was obtained by micromanipulation
cloning from FCR3S1 (19), a parasite previously cloned by limit-
ing dilution (25). The parasites were cultured according to stan-
dard methods.
 
The Adherence of Soluble Receptors to pRBCs of FCR3S1.2.
 
The infected erythrocytes of FCR3S1.2 were studied for their ca-
pacity to adhere to soluble fluorescence-labeled receptor proteins
as follows. A 200 
 
m
 
l aliquot of the resuspended parasite culture of
an 
 
z
 
8% parasitemia and a 5% hematocrit was washed three times
with 100 mM Nacitrate in PBS and once in PBS before adding
different receptors as specified below. The binding was examined
under incident UV light using a Nikon Optiphot-2 after a room
temperature 60-min incubation on a rotator, three washes with
PBS, and counterstaining with ethidium bromide (0.001% in
PBS). The estimation of IgM binding was performed as described
previously (11).
Blood group A antigen (GalNAc-1-3Gal-2-1-Fuc) bound to
biotinylated BSA via a spacer (-
 
O
 
-
 
p
 
-trifluoroacetamidophenyl-
ethyl) was purchased from IsoSep. The trisaccharide-biotin-BSA
conjugates or control biotin-BSA were diluted in double dilu-
tions from 200 to 50 
 
m
 
g/ml in PBS and mixed with a 200 
 
m
 
l ali-
quot of the culture as above. An FITC-avidin conjugate (1:100
dilution; Sigma-Aldrich) was added after a 60-min room temper-
ature incubation and three washes in PBS. The binding was visu-
alized as outlined above.
Soluble PECAM-1/CD31 purified from Chinese hamster
ovary (CHO) cells (cat. no. ADP6) was purchased from R&D
Systems. Four distinct CD36–glutathione 
 
S
 
-transferase (GST) fu-
sion proteins covering amino acids (aa) 67–298 were expressed
and purified from 
 
Escherichia
 
 
 
coli 
 
and held in PBS with 1% Triton
X-100 (26). 500 
 
m
 
g of a mixture of the four CD36 fusion pro-
teins was labeled with the fluorescent dye Alexa 488 according to
the protocols of the producer (Molecular Probes). Intracellular
adhesion molecule 1 (ICAM-1) and PECAM-1/CD31 were sim-
ilarly directly labeled with Alexa 488. The fluorescence-labeled
receptors (CD36, CD31, and ICAM-1) were added at double di-
lutions ranging from 200
 
 
 
to 50 
 
m
 
g/ml to the parasite culture as
above after three washes in PBS. The binding was visualized as
outlined above.
 
Adherence of pRBCs to Receptors Expressed on Transfected CHO or
L Cells.
 
The methods used were as described (7) with some mi-
nor modifications. In brief, the binding of pRBCs of FCR3S1.2
was assessed with the cells adherent to coverslips. CHO cells (K1/
CCL61), transfected CHO cells expressing CD36 at the cell sur-
face (CHO-CD36), L cells, or transfected L cells expressing PE-
CAM-1/CD31 (L cell–PECAM-1/CD31) were seeded at a den-
sity of 
 
z
 
25,000 cells/coverslip (Thermonox; Nunc) and cultured
in RPMI 1640 with 0.6% Hepes, 0.2% NaHCO
 
3
 
, 10% FCS, 0.5
mg/ml gentamicin, and 1% penicillin-streptomycin for 2 d before
use (37
 
8
 
C, 2% CO
 
2
 
). The pRBCs to be assayed were fractionated
on a Percoll gradient (19) to yield 
 
z
 
95% late stage–infected
RBCs, which were resuspended in binding medium (RPMI
1640, 25 mM Hepes, 25 
 
m
 
g/ml, pH 6.8). 1 ml of a 2% hemat-
 
ocrit suspension of the pRBCs was overlaid on the transfected
cells and incubated at 37
 
8
 
C for 60 min with gentle rocking every
now and then. The cells were washed three times with binding
medium and stained with Giemsa. The number of pRBCs bound
per 100 CHO or L cells was estimated counting a minimum of
500 cells for the determination of the binding capacity of the
pRBCs.
 
Cloning and Expression of DBL1
 
a
 
, CIDR1
 
a
 
, and DBL2
 
d
 
 of
FCR3S1.2
 
var1
 
 in E. coli.
 
The cloning and expression of DBL1
 
a
 
and the acidic terminal segment (ATS) were conducted as de-
scribed (12). Gene fragments encoding CIDR1
 
a
 
 (aa 516–822)
and DBL2
 
d
 
 (aa 905–1307) were PCR amplified with primers
(C1 5
 
9
 
-TCC AAC ATA AAG GTG GTA ATC AA-3
 
9
 
 and C2
5
 
9
 
-TGT CTT ACC ATC ACT TAT ACA A-3
 
9
 
 for CIDR1
 
a
 
;
D4.1 5
 
9
 
-TCA CCG GAG TAC GAC CCA-3
 
9
 
 and D4.2 5
 
9
 
-
ATT TTC TAC TTT ACA ATC CAC TTT-3
 
9
 
 for DBL2
 
d
 
),
cloned in the pGEX-4T plasmid (Amersham Pharmacia Biotech),
and expressed in 
 
E
 
.
 
 coli
 
 (BL21). The GST fusion proteins were
expressed and purified according to the instructions of the manu-
facturer (12, 27). The purity was determined by using SDS-
PAGE and Western blot as described (12).
 
Binding of Recombinant DBL1
 
a
 
, CIDR1
 
a
 
, and DBL2
 
d
 
 to Re-
ceptors on Solid Phase.
 
The interaction of recombinant DBL1
 
a
 
-
GST, CIDR1
 
a
 
-GST, and DBL2
 
d
 
-GST with different receptors
was first studied using a solid phase assay system. 100 
 
m
 
l of CD36,
PECAM-1/CD31, IgM, or E-selectin was coated in ELISA
plates (cat. no. 3455; Immulon) at a concentration of 5 
 
m
 
g/ml in
NaHCO
 
3 
 
buffer (pH 9.5) overnight at 4
 
8
 
C. The plates were sub-
sequently blocked for 1 h at room temperature with 3% BSA in
PBS. 100 
 
m
 
l of serially double-diluted DBL1
 
a
 
-GST, CIDR1
 
a
 
-
GST, DBL2
 
d
 
-GST, or GST (100 to 0.75 
 
m
 
g/ml) was added to
each well and incubated at room temperature for 60 min. Biotin-
labeled anti-GST mAb (G-1160, IgG2b, 1:600 dilution; Sigma-
Aldrich) and streptavidin–alkaline phosphatase (ALP) (1:1,000
dilution; Sigma-Aldrich) were then added to detect the fusion
proteins after three washes in PBS-Tween. A final 100 
 
m
 
l of sub-
strate buffer was added to each well after three washes in PBS-
Tween, and each reaction was determined with an automatic
ELISA reading system at OD 405 nm. Each experiment was re-
peated three times, and the final results shown are the means 
 
6 
 
2
SD. The background binding generated by GST alone was al-
ways negligible but deduced before the calculations. In the case
of blood group antigen binding, the fusion proteins (DBL1
 
a
 
-
GST, CIDR1
 
a
 
-GST, DBL2
 
d
 
-GST, and GST; 10 
 
m
 
g/ml) were
coated on ELISA plates as above. Biotinylated BSA coupled with
the blood group A antigen or biotin-BSA were serially double
diluted from 100 to 0.75 
 
m
 
g/ml and incubated with each fusion
protein for 60 min at room temperature followed by three
washes with PBS-Tween. 100 
 
m
 
l of substrate buffer was added
to each well after a further incubation with streptavidin-ALP
(1:1,000 dilution; Sigma-Aldrich) and three washes in PBS-
Tween. The results were assessed as above. For testing heparin
binding activity of the three domains, 100 
 
m
 
l of serially double-
diluted DBL1
 
a
 
-GST, CIDR1
 
a
 
-GST, DBL2
 
d
 
-GST, or GST
(100 to 0.75 
 
m
 
g/ml) was incubated with 20 
 
m
 
l of heparin-
sepharose (Amersham Pharmacia Biotech) for 30 min followed
by three washes with PBS-Tween. The beads were transferred to
an ELISA plate after further incubation with biotin-labeled anti-
GST antibodies and streptavidin-ALP. The binding was assessed
as above.
 
Binding of Recombinant DBL1
 
a
 
, CIDR2
 
a
 
, and DBL2
 
d
 
 to Cells
Expressing CD36 or PECAM-1/CD31.
 
CHO cells, CHO-CD36,
L cells, or L cell–PECAM-1/CD31 were cultured in normal me- 
3
 
Chen et al.
 
dium for 2 d before the assays. The cells were detached with a
rubber policeman and suspended in PBS. Serially double-diluted
fusion proteins (DBL1
 
a
 
-GST, CIDR1
 
a
 
-GST, DBL2
 
d
 
-GST,
and GST) from 200 to 50 
 
m
 
g/ml were added to the cell suspen-
sions (200 
 
m
 
l) and incubated at room temperature for 60 min.
The cells were washed three times with PBS and subsequently
stained with an Alexa 488 (Molecular Probes) labeled anti-GST
mAb (G-1160, 1:100 dilution; Sigma-Aldrich) for 60 min. Sur-
face fluorescence was studied under incident UV light as above
after three washes in PBS.
The importance of glycosylation for the binding of the recom-
binant fusion proteins to CHO cells was also studied. Normal
CHO cells and CHO-CD36 were cultured for 2 d with or with-
out the addition of tunicamycin (1 mg/ml; see also reference 28)
in the culture medium. The cells were detached with a rubber
policeman and suspended in PBS. Some of the cells not treated
with tunicamycin were further incubated with heparinase (8.5 3
1023 IU/ml) for 3 h at 258C. The cells were washed three times
in PBS, and the binding assay was performed as above.
Cloning DBL1a, CIDR1a, and DBL2d of FCR3S1.2var1 in
pRE4 Vector and Transfection of COS-7 Cells. For transient ex-
pression of FCR3S1.2var1 gene fragments encoding DBL-1,
CIDR1a, and DBL2d on the surface of COS-7 cells, the three
domains were PCR amplified with the following three pairs of
primers: DBL1a with DL-1.1 59-ATC GAT CAG CTG CCG
TGC AAA AAA GAT GGA A-39 and DL-1.2 59-ATC GAT
GGG CCC TGA TAT TTC TTT TGT GTA TTT-39;
CIDR1a with CR-1 59-ATC GAT CAG CTG ACT AGT
GGT GCT AGT GGT A-39 and CR-2 59-ATC GAT GGG
CCC GTC TTT TAT TGG CTT CCA TTC-39; and DBL2d
with DL-4.1 59-ATC GAT CAG CTG ACA CCA AGT GGT
GAA CC-39 and DL-4.2 59-ATC GAT GGG CCC CCG ACA
GAA ACT CTC TCC-39. The PCR product of each amplifica-
tion was precipitated with ethanol. Both the PCR products and
the pRE4 vector were digested with ApaI and PuvII. The frag-
ments were further purified after digestions from agarose using
standard methods. 1 ml of the digested vector and each PCR
fragment were mixed for ligation at room temperature for 4 h. 3
ml of each ligation solution was used to transform competent bac-
terial cells (Top10F9; Invitrogen). The bacterial clones with cor-
rect recombinant plasmids were determined by PCR amplifica-
tion with two primers (Sig-1, 59-GTG ATT TTG TTT GCT
GTC ATA-3 and Tm-1 59-CAG CAG GGT GCT CGT GTA-
39). The sequences of the three constructs were further deter-
mined by sequencing. The plasmids were isolated with a Plasmid
Isolation kit (Bio-Rad Laboratories). 1 mg of each recombinant
plasmid (DBL1a-pRE4, CIDR1a-pRE4, DBL2d-pRE4, or the
vector pRE4) was purified with the Plasmid Midiprep kit (Invit-
rogen). The plasmids were dissolved in 1 ml of sterile dH2O (1
mg/ml) and kept at 2208C for later use.
COS-7 cells from the American Tissue Culture Collection
were routinely cultured in a normal DMEM (Life Technologies,
Inc.) containing 10% heat-inactivated FCS. The cells were seeded
on coverslips in 12-well culture plates overnight or until 50–60%
confluence. 4 mg of the plasmid was mixed with 24 mg of lipo-
some (Invitrogen) in 2 ml DMEM without serum and incubated
for 5 min at room temperature. The COS cells were washed once
with PBS, and the transfection solutions were applied to the cells
immediately. After 4 h of transfection, the transfection solutions
were removed and replaced with normal COS cell medium. The
cells were cultured at 378C in a CO2 incubator for 48 h. The ex-
pression of DBL1a, CIDR1a, and DBL2d on the COS cell sur-
face was confirmed through the surface immunofluorescence by
using mAbs ID3 or DL6, which recognize a short sequence of
herpes simplex virus glycoprotein D that is expressed by the vec-
tor on either side of the insert as described (29, 30).
Binding of Soluble Receptors to Transfected COS-7 Cells. Hu-
man myeloma IgM (Jackson ImmunoResearch Laboratories), re-
combinant CD36, and PECAM-1/CD31 were directly labeled
with Alexa G-448 as above and kept at 48C before use. 1 ml of
different dilutions of the receptors (from 200 to 50 mg/ml in
PBS) was incubated with COS cells transfected with the construct
Figure 1. The binding of fluorescence-labeled soluble receptors to the
surface of erythrocytes infected with FCR3S1.2. Fluorescence-labeled re-
combinant human CD36, ICAM-1, or PECAM-1/CD31 was directly
incubated with the infected cells. The binding of human nonimmune
IgM was detected by incubating the pRBCs with FITC-labeled rabbit
anti–human Ig, whereas that of the blood group antigen A was by incu-
bating the infected cells with an A trisaccharide coupled to biotinylated
BSA and FITC-avidin. Infected (arrows) and uninfected RBCs are shown
with phase–contrast (PC) and in parallel with UV light (UV). The bind-
ing shown was at a receptor concentration of 100 mg/ml, and the para-
sites were counterstained with ethidium bromide. The fluorescence rates
were 65–70% (CD36), 0–5% (ICAM-1), 70–80% (PECAM-1/CD31),
75–85% (IgM), and 60–70% (blood group A). For further details, see Ma-
terials and Methods.4 P. falciparum Erythrocyte Membrane Protein 1 Is Multiply Adhesive
(DBL1a-pRE4, CIDR1a-pRE4, DBL2d-pRE4, or pRE4) for 60
min. After the incubation, the cells were washed three times with
either RPMI 1640 or PBS. The fluorescence was estimated with
cells either on coverslips or in suspension.
Erythrocyte Binding to Transfected COS-7 Cells. Aliquots of blood
group A1 and O Rh1 erythrocytes were treated with heparinase
as described (12). Both untreated and heparinase-treated RBCs
were subsequently washed three times with RPMI 1640 and re-
suspended in malaria culture medium. 1 ml of a 2% erythrocyte
suspension was added to the COS-7 cells transfected with
DBL1a, CIDR1a, or DBL2d or to untransfected COS cells and
incubated at 378C for 60 min as described (10, 30). The cells
were washed with binding buffer, and the rosetting rate was as-
sessed as described (10).
Results
FCR3S1.2-infected Erythrocytes Bind Soluble Receptors.
To ascertain the adhesive profile of the pRBCs of
FCR3S1.2, we studied the binding of various soluble fluo-
rescence-labeled receptors to the live pRBC surface in-
cluding the blood group A antigen, CD36, PECAM-1/
CD31, heparin, and human IgM. Prominent binding of all
of the receptor conjugates except soluble ICAM-1–fluo-
rescein was seen to the pRBC surface (Fig. 1; heparin-
FITC, not shown). The labeling varied in intensity be-
tween the different conjugates: the PECAM-1/CD31 and
soluble CD36 fluorescence was the strongest, showing an
even distribution all around the pRBC surface (Fig. 1).
The adherence of all of the soluble receptors to the pRBCs
of a sister clone (FCR3S1.6) (19) that lacks adhesive prop-
erties was also studied, but no or very weak binding was
seen. These findings confirm the specificity of the assays
and the panadhesive profile of this parasite clone, which is
also summarized in Table I (see also references 7, 11, 13,
and 19).
Binding of Recombinant PfEMP1 to Multiple Receptors. Do-
main-like recombinant fragments (DBLIa-GST, CIDR1a-
GST, DBL2d-GST, and GST as control) of the PfEMP1 of
FCR3S1.2 were expressed and purified from E. coli and
used to dissect the binding to different receptors or re-
ceptor proteins. The various fusion proteins were tested
in ELISA assays for their capacity to adhere to the blood
group A antigen, PECAM-1/CD31, CD36, E-selectin,
heparin, and IgM (Fig. 2). We also studied the binding
activities of recombinant DBL1a-GST, CIDR1a-GST,
DBL2d-GST, or GST to normal CHO cells (K1/CCL61),
transfected CHO cells expressing CD36, normal L cells, or
transfected L cells expressing PECAM-1/CD31 (Fig. 3).
The binding of DBL1a, CIDR1a, and DBL2d to the
panel of receptors was further examined using a COS cell
expression system in which the PfEMP1 domains cloned
into the pRE4 vector were expressed at the surface of the
COS cells (Fig. 4).
CIDR1a Mediates Binding to CD36. Both the CIDR1a
and the DBL2d domains bound in an ELISA assay in
which human CD36 was coated on the plates whereas the
other fusion proteins (DBL1a-GST and GST) were not
(Fig. 2). The CIDR1a-GST also bound to CHO cells ex-
pressing CD36, whereas binding to DBL2d-GST was
weak (Fig. 3) and neither DBL1a-GST nor GST bound to
these cells when heparinase treated (Fig. 3, and data not
shown). The binding of CD36 to the PfEMP1 domains
(DBL1a, CIDR1a, and DBL2d) was further studied using
the COS cell expression system. COS cells expressing
CIDR1a specifically bound CD36 (Fig. 4 and Table II),
whereas neither COS-DBL1a, COS-DBL2d, nor the un-
transfected COS cells showed any binding to CD36.
Thus, it seems that CIDR1a is the critical PfEMP1 do-
main involved in CD36 binding but that DBL2d could
also play a part.
CIDR1a and DBL2d Bind to PECAM-1/CD31. Both
the CIDR1a and the DBL2d domains bound in an ELISA
assay in which human PECAM-1/CD31 was coated on
the plates, whereas the other fusion proteins (DBLIa-GST
and GST) were not (Fig. 2). The CIDR1a-GST and
DBL2d-GST both also bound to L cells (.60% fluores-
cence rate) expressing PECAM-1/CD31, whereas neither
DBL1a-GST nor GST bound to these cells (Fig. 3, and
data not shown). Again, the binding of PECAM-1/CD31
to the PfEMP1 domains (DBL1a, CIDR1a, and DBL2d)
was further studied using the COS cell expression system.
COS cells expressing CIDR1a or DBL2d did specifically
bind PECAM-1/CD31 (Fig. 4, and Table II) whereas nei-
ther COS-DBL1a nor the untransfected COS cells showed
any binding to PECAM-1/CD31.
To delineate the relative importance of either CIDR1a
or DBL2d in adherence of PECAM-1/CD31 to the
pRBCs, we investigated the capacity of the recombinants
Table I. Adhesive Phenotypes of the Infected Erythrocytes of P. 
falciparum Clone FCR3S1.2
CHO-CD36 binding* 400 6 50
CHO–ICAM-1 binding* 40 6 12
CHO binding* 6 6 3
L cell–PECAM-1/CD31 binding* 800 6 80
L cell binding* <5
Thrombospondin‡ 0
IgM binding§ <90%
IgG binding§ <20%
Blood group A antigen bindingi <90%
Heparin-like GAG bindingi <90%
Rosetting¶ 90 6 5%
Autoagglutination** .40%
*Number of late stage pRBCs bound per 100 cells.
‡Number of late stage pRBCs bound to thrombospondin-coated plas-
tic (50 mg/ml).
§Percentage of late stage pRBCs showing surface fluorescence when
incubated with antibodies to human nonimmune IgM or IgG.
iPercentage of late stage pRBCs showing binding to a heparin-like
GAG or the blood group ABO antigens (see references 8, 12).
¶Percentage of late stage pRBCs forming rosettes (rosetting rate) in
blood group O Rh1 RBCs.
**Percentage of late stage pRBCs forming autoagglutinates.5 Chen et al.
Figure 2. The interaction of the recombinant
PfEMP1 domains (DBL1a, CIDR1a, and DBL2d) as
GST fusion proteins with different receptors (CD36,
PECAM-1/CD31, blood group antigen A, heparin,
and E-selectin) or receptor proteins (IgM) bound to
solid phase as measured by ELISA. The domain-like
primary structure of FCR3S1.2var1-PfEMP1 is shown at
the top of the figure (colored boxes). Each receptor
studied (left) for interaction with a GST fusion protein
is shown as a separate curve (DBL1a, blue d;
CIDR1a, pink s; DBL2d, violet e). The ranges of
absorption values are shown on the y-axis and the con-
centrations (in mg/ml) on the x-axis. The results are
the mean of at least three separate experiments 6 2 SD.
For further details, see Materials and Methods.
Figure 3. The interaction of the recombinant PfEMP1 domains (DBL1a, CIDR1a, and DBL2d) as GST fusion proteins with receptors expressed on
normal or transfected cells (some of the cells were treated with heparinase to remove HS from the cell surface) visualized by a fluorescence-labeled anti-
GST antibody. The results are those of at least three separate experiments. 95% untreated and 5% treated CHO cells (CHO and CHO-CD36) bind
DBL1a, respectively. More than 80% untreated CHO-CD36 cells bind CIDR1a, whereas ,30% CHO-CD36 bind DBL2d. For further details, see
Materials and Methods.6 P. falciparum Erythrocyte Membrane Protein 1 Is Multiply Adhesive
(DBL1a-GST, CIDR1a-GST, DBL2d-GST, and GST) to
abrogate the binding of fluorescence-labeled sPECAM-1/
CD31. Inhibition was obtained with both the CIDR1a
and the DBL2d domains (40% inhibition at 200 mg/ml for
CIDR1a; 60% inhibition at 200 mg/ml when CIDR1a
and DBL2d were mixed at a ratio of 1:1, 100 mg/ml each),
whereas no inhibition was seen with either DBL1a-GST
or GST. The CIDR1a domain was somewhat more effi-
cient in binding inhibition than DBL2d (data not shown).
Thus, it seems that both CIDR1a and DBL2d are involved
in PECAM-1/CD31 binding.
CIDR1a Binds IgM. The binding of the three fusion
proteins (DBL1a-GST, CIDR1a-GST, and DBL2d-GST)
and GST to ELISA plates precoated with human IgM
clearly showed that the CIDR1a region bound to this se-
rum protein (Fig. 2). Neither DBL1a, DBL2d, nor GST
had the capacity to bind IgM (Fig. 2, and data not shown).
Further, in complementary experiments we similarly found
that CIDR1a-transfected COS cells did specifically bind
IgM whereas neither COS-DBL1a, COS-DBL2d, nor the
untransfected COS cells were able to bind immunoglobu-
lins (Fig. 4, and Table II). Taken together, the data suggest
that CIDR1a is the PfEMP1 domain that binds normal
nonimmune IgM.
DBL1a Mediates Rosetting through an HS-like GAG and
the Blood Group A Antigen. Potential GAG-binding mo-
tifs (31) were identified in all three PfEMP1 domains of
FCR3S1.2var1 (12) and, as expected, all three GST fusion
proteins (DBL1a-GST, CIDR1a-GST, and DBL2d-GST)
bound dose-dependently to heparin-sepharose (Fig. 2)
whereas no binding was seen with GST alone (data not
shown). To confirm these findings, we studied the inter-
action of recombinant DBL1a-GST, CIDR1a-GST,
DBL2d-GST, or GST alone to normal CHO cells, trans-
Figure 4. The binding of fluorescence-labeled receptors, receptor proteins, or erythrocytes to COS-7 cells transiently transfected with the different
PfEMP1 domains (DBL1a, CIDR1a, and DBL2d) of FCR3S1.2var1. The transfected cell type used is shown at the top of the figure. The fluorescence-
labeled protein or erythrocyte used is shown in the right hand corner of each photograph. The results are those of at least three separate experiments. For
further details, see Materials and Methods.
Table II. Binding of Different Receptors and RBCs to var 
Fragment–transfected COS-7 Cells
COS-DBL1a COS-CIDR1a COS-DBL2d
Transfection
efficiency 1–3% 6–8% 3–6%
IgM* 212
CD36* 212
PECAM-1/CD31* 211
O Rh1 RBCs‡ 50 6 15 0 0
O Rh1 RBCs
(heparinase treated)‡ 0N D N D
A1 RBCs‡ 45 6 20 0 0
A1 RBCs
(heparinase treated)‡ 40 6 15 ND ND
*The binding to transfected COS-7 cells was detected by directly incu-
bating fluorescence-labelled receptors with the cells.
‡Average number of RBCs bound to the transfected COS-7 cells.7 Chen et al.
fected CHO cells expressing CD36 at the cell surface, or
transfected L cells expressing PECAM-1/CD31. Surpris-
ingly, DBL1a-GST, but not the other recombinant pro-
teins (CIDR1a-GST, DBL2d-GST, or GST), bound to all
CHO cells including the nontransfected ones. This sug-
gested that DBL1a-GST might adhere to HS-like GAGs.
Further proof of this specificity was generated, as it was
found that the binding activity was abrogated when the
CHO cells were cultured in the presence of tunicamycin (1
mg/ml) for 2 d or when the cells were treated with hepari-
nase (8.5 3 1023 IU/ml) before the binding assays (Fig. 3).
The binding of DBL1a to the CHO cells is therefore most
likely to be mediated via HS-like molecules on the CHO
cell surface. The involvement of DBL1a, CIDR1a, or
DBL2d in HS-mediated binding at the cellular level was
further studied using a COS cell expression system. The
COS-DBL1a did bind blood group O RBCs, whereas the
other transfectants did not (COS-CIDR1a, COS-DBL2d,
and COS; Table II and Fig. 4). The binding of blood
group O RBCs to COS-DBL1a could again be abrogated
by the pretreatment of the erythrocytes with heparinase
(8.5 3 1023 IU/ml). Taken together, the data confirm our
findings that DBL1a has high affinity for an HS-like GAG
expressed on the erythrocyte surface and suggest that the
other two domains, CIDR1a and DBL2d, are less involved
in this interaction. Recombinant DBL1a-GST also bound
dose-dependently to the trisaccharide GalNAc-Gal-Fuc
(blood group A antigen linked to BSA), whereas the other
two PfEMP1 domains (CIDR1a-GST and DBL2d-GST;
Fig. 2) and GST alone did not (data not shown). COS
cells transiently transfected with DBL1a bound both
blood group O and A erythrocytes, whereas neither
COS-CIDR1a– nor COS-DBL2d–expressing cells or the
untransfected COS cells did so (Table II and Fig. 4). Im-
portantly, while the binding of blood group O RBCs to
COS-DBL1a was abrogated when the erythrocytes were
pretreated with heparinase (8.5 3 1023 IU/ml), the bind-
ing of blood group A RBCs to COS-DBL1a still remained
after heparinase treatment even though the number of
RBCs bound to the COS-DBL1a–expressing cells was
somewhat reduced (Table II). These data show that
DBL1a has affinity for the blood group A antigen.
Discussion
The data presented in this report demonstrate that P. fal-
ciparum–infected erythrocytes may bind to a large number
of diverse receptors through a single species of PfEMP1.
The expression of PfEMP1 by FCR3S1.2 at the infected
RBC surface was previously established by both surface
iodination and immunoprecipitation using specific anti-
PfEMP1 antibodies (12, 19, 27). A PfEMP1 polypeptide
with a molecular mass of z280 kD was identified. Immu-
noprecipitation and transcript analysis of single cells further
indicated that the parasite expresses only one species of
PfEMP1 at the infected erythrocyte surface (27), a fact that
has been repeatedly confirmed throughout this study. Anti-
bodies raised to the FCR3S1.2var1 DBL1a domain have
been found to stain live infected erythrocytes, confirming
that it is var1 that encodes the PfEMP1 of FCR3S1.2 (data
not shown). Mild trypsinization of infected RBCs of
FCR3S1.2 readily deleted the PfEMP1 from the cell sur-
face, at least the iodinated portion, and the adhesive events
incurred by this parasite (32). We have also found, in re-
cent experiments not presented here, that immunoglobu-
lins, heparin, or blood group A can selectively precipitate
radioiodinated PfEMP1 from FCR3S1.2. This suggests that
it is PfEMP1 that mediates the major binding events of this
parasite.
The binding of DBL1a to GAGs is structurally specific
for heparin or HS/HS-like GAGs and dependent on a
2-N-sulfated glucosamine, as is the rosetting binding of intact
Figure 5. Schematic summary of the dif-
ferent binding activities of the DBL1a,
CIDR1a, and DBL2d domains of PfEMP1
encoded by FCR3S1.2var1. P. falciparum ex-
presses PfEMP1 molecules (here shown
corkscrew-like) on a knob-like structure at
the infected erythrocyte surface. The
DBL1a domain participates in rosetting
through binding to an HS-like GAG and to
the blood group A antigen. The CIDR1a
domain binds to CD36 and to members of
the immunoglobulin superfamily, includ-
ing IgM and PECAM-1/CD31, whereas
the DBL2d domain binds mainly to PE-
CAM-1/CD31.8 P. falciparum Erythrocyte Membrane Protein 1 Is Multiply Adhesive
cells (13). All three domains (DBL1a, CIDR1a, and
DBL2d), as expected, were found to bind to heparin-
sepharose, but it is not likely that the CIDR1a and the
DBL2d domains avidly participate in the cellular interac-
tions leading to rosette formation. Arguing for this are the
findings that only the DBL1a domain and not CIDR1a or
DBL2d bound to HS-like GAGs on normal CHO cells.
Further, only the DBL1a domain and not CIDR1a or
DBL2d supported binding of erythrocytes when the do-
mains were expressed at the surface of COS cells. Taken
together, the data suggest a prominent role for DBL1a and
an HS-like GAG in the formation of stable rosettes.
Individuals of the blood group A antigen type have been
found to come down with severe disease more frequently
than those of other ABO blood groups (33). Importantly,
the blood group A antigen has also been discovered to be a
receptor mediating rosetting of both fresh isolates and labo-
ratory-adapted strains (8, 34). Blood group antigen–depen-
dent rosetting has been found to be as sensitive to trypsin
as is PfEMP1 (19) and, further, PfEMP1 encoded by
FCR3S1.2var1 can be precipitated from the parasite using a
polymerized blood group A antigen. Here, with the help of
four additional experimental systems, we provide evidence
that it is the DBL1a domain of PfEMP1 that mediates
binding to the blood group antigens.
The infected erythrocytes of FCR3S1.2 also display ad-
hesive features other than rosetting. This motivated us to
check all three PfEMP1 domains for binding to serum pro-
teins and endothelial receptors such as IgM, CD36, PE-
CAM-1/CD31, and E-selectin. Surprisingly, DBL1a did
not adhere to any of these receptors. On the other hand,
dramatic binding was seen with CIDR1a to CD36, PE-
CAM-1/CD31, and IgM, whereas DBL2d had PECAM-
1/CD31 as the main specificity. Not one of the fusion pro-
teins bound to E-selectin (Fig. 2). These findings are the
condensation of results of a large number of in vitro assays.
Still, some uncertainty remains on the importance for ad-
herence of DBL2d to CD36, as weak binding was seen in
both the solid phase and in the CHO-CD36 assay, whereas
no binding of CD36 was detected to DBL2d-transfected
COS cells. Baruch et al. (24) have shown that CIDR1a
binds to CD36 via a peptide–peptide interaction involving a
degenerate CIDR1a sequence containing multiple con-
served cysteine residues, a sequence which is also present in
the CIDR1a of FCR3S1.2var1 PfEMP1. Thus, it seems
likely that the CIDR1a domain plays a major role in endo-
thelial binding to CD36. When we tested the binding of the
three domains (DBL1a, CIDR1a, and DBL2d) to ICAM-1,
some affinity for CIDR1a was also observed but it was weak
(data not shown). Yet it is tempting to suggest that CIDR1a
has an affinity for a structure present in the members of the
immunoglobulin superfamily studied (IgM and PECAM-1/
CD31) but a separate binding site for CD36. The details of
the adhesive interactions of CIDR1a are complex, and the
relative importance of the interactions characterized could
very well vary in different situations and at different time
points depending on the availability of each receptor at each
vascular location in the same host.
In conclusion, the data here show that three PfEMP1
domains (DBL1a, CIDR1a, and DBL2d) of one PfEMP1
species mediate multiple independent interactions with a
diverse set of host receptors, as summarized in Fig. 5. The
findings provide a molecular explanation of the multiadhe-
sive phenotype of P. falciparum and suggest its importance
in the development of severe malaria. The DBL1a-
CIDR1a head structure may also prove to be an important
vaccine candidate, particularly if antibodies directed to
conserved determinants in DBL1a-CIDR1a are common
in those protected against severe malaria.
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